In the last two years at the Royal Free Hospital 45 patients were admitted with bleeding cesophageal varices. The mean number of units (pints) of blood required for transfusion in the first 24 hours was 3-8 and the mean total during that hospital admission was 11 units; the clinician must be prepared for re-bleeding, for this was noted in 32 of the 45 patients. The overall mortality for this group was 44 %. The mortality was only 18% in those with the milder haemorrhages who required only 5 units of blood or less; the mortality after this did not increase with the amount of blood transfused, being 50-60% in patients receiving up to more than 20 units (Fig 2) . Three patients required more than 40 units and one of these survived after a record of 52 units of blood transfused. Of course such statistics take no account of other factors, particularly the extent of liver failure, which are the real determinants in survival after bleeding cesophageal varices (Sherlock 1963) . The transfusion of such large quantities raised the possibility of citrate intoxication; this would be expected to be more common in those with liver disease, for the liver metabolizes citrate. A citric acid tolerance test has even been used to assess liver function. Very high concentrations of serum citrate have been observed during multiple transfusions in liver disease or in those with mechanical obstruction to the hepatic circulation (Bunker et al. 1955) ; these have been sufficient to depress the ionized calcium values significantly. In general, however, it has been doubted whether citrate intoxication is a real clinical problem even in those with hepatic dysfunction (Howland et al. 1957) ; much depends on the speed of transfusion; when one unit is transfused in five minutes difficulties may occur.
Spontaneous fibrinolytic activity has been known for some time in patients with chronic liver disease. This has been shown particularly after portacaval anastomosis when an increased tendency to operative and post-operative bleedings has been related to active fibrinolysis (Grossi et al. 1962 ). The liver probably produces an inhibitor of fibrinolysin (von Kaulla 1964 , O'Connell et al. 1964 ). An excellent example of this is seen with hepatic transplantation (Starzl et al. 1963 ). For some time during the operation the patient is virtually without a liver while the donor (cadaver) liver is being inserted: the fibrinolysis time (euglobulin lysis time) falls dramatically. This time measures inhibition of the fibrinolysis, which is followed by a fall in fibrinogen. This reaction is controlled by fresh blood transfusion, fibrinogen infusions and by e-aminocaproic acid (EACA); then follows a period of increased blood coagulability. Starzl and his group (1964, personal communication) have performed 5 hepatic transplants in man using cadaver -donors: 4 recipients suffered from carcinoma of the liver and one, a child, from biliary atresia. One patient died during the operation from hemorrhage and showed very low fibrinogen levels; one patient died twentythree days later from disruption of the bile ducts, presumably part of a rejection reaction; 3 died of pulmonary emboli six, eight and twenty-two days post-operatively. The problem of blood coagulation is one of the deterrents from gaining more experience with hepatic transplantation in man.
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Acute Fibrinolytic States in Surgery
Over the past decade evidence has accumulated that one cause of acute failure of hemostasis during surgical operations is pathological fibrinolytic activity. It is the purpose of this paper to give a brief account of the components and functions of the fibrinolytic enzyme system, of the mechanism by which it may cause hiemostatic defects and of the diagnosis and treatment of such defects. A recent issue of the British Medical Bulletin (Vol. 20, No. 3, September 1964) was exclusively devoted to fibrinolysis and should be consulted for a fuller discussion of the physiological and biochemical considerations.
According to current concepts the fibrinolytic enzyme system, or plasminogen-plasmin system, probably has a physiological role complementary to that of the coagulation system in maintaining an intact patent vascular tree. The two systems are probably in a state of dynamic equilibrium. The coagulation system seals, with a himostatic fibrin plug, any deficiencies in the vascular endothelium and the fibrinolytic enzyme system removes such fibrin deposits after endothelial repair has taken place. The fibrinolytic enzyme system probably also has a role in removing fibrin deposits in the tissues. The fibrinolytic enzyme system is complex but its main components are plasminogen, plasmin, activators and inhibitors. Plasminogen, a normally inert plasma globulin, is converted by activators to plasmin, a proteolytic enzyme which can digest many proteins including fibrinogen, fibrin, antiheemophilic globulin (AHG) and Factor V. Activators of plasminogen include a plasma activator, tissue activators present in especially high concentrations in prostate, lungs, thyroid and uterus, and a urinary activator named urokinase. Certain bacteria also produce plasminogen activators, e.g. streptokinase from streptococci. Small amounts of plasminogen activator are probably constantly present in the plasma in physiological circumstances and, in physiological circumstances, inhibitory mechanisms restrict plasmin to digestion of fibrin. Plasma contains more antiplasmin than plasminogen and, provided plasma plasminogen activation is slow, plasmin as it is produced is neutralized by antiplasmin. On the other hand, when plasma activator diffuses into fibrin deposits, where effective antiplasmin levels are low, plasminogen is converted to plasmin in close association with fibrin which is digested.
If large amounts of plasminogen activator are suddenly released into the circulation, plasminogen is suddenly and completely converted to plasmin and there is temporary overwhelming of the antiplasmin mechanism, with the appearance of free plasmin in the circulationhyperplasminemia. In consequence of proteolytic activity in the circulation, plasma proteins including fibrinogen, Factor VIII and Factor V are digested and a grave coagulation defect ensues. An important consequence of fibrinogen digestion is defective fibrin polymerization, as one of the breakdown products of fibrinogen proteolysis by plasmin interferes with the conversion of fibrin monomer to fibrin polymer during the final phase of the coagulation process. The direct effect of depletion of coagulation factors and accelerated clot lysis also contribute to the hyperplasminemic coagulation defect.
Causes ofHyperplasminwmia
Hyperplasminemic states, due to sudden release of plasminogen activator into the circulition, may complicate any major surgical operation, espec-10 ially when Lissues rich in plasminogen activator have been handled. They are particularly liable to complicate thoracic surgery, especially cardiac surgery with a heart-lung machine. The evidence suggests that a minor hyperplasminsemic coagulation defect occurs in most major surgical operations; the reasons why the defect assumes major proportions in a few cases only are not understood though severe hypotension and cardiac arrest seem to be precipitating factors in some cases. Hyperplasminemia may also occur after any severe trauma, in obstetric accidents, cirrhosis of the liver, carcinoma of the prostate with metastases and possibly occasionally in leukemia. In some cases at least, thromboplastin release into the circulation may accompany or precede plasminogen activator release and a complex picture, due in part to intravascular clotting and in part to fibrinolysis, may be found.
Diagnosis ofHyperplasminemic States
This diagnosis should be suspected when a patient with a predisposing clinical condition is found to have a generalized hiemostatic defect with either incoagulable blood or a prolonged whole-blood clotting time. The diagnosis is supported by accelerated whole clot lysis times. Other laboratory tests include prolonged prothrombin times and prolonged thrombin time (the time taken for a clot to form in citrated plasma on addition of thrombin under standardized conditions), low fibrinogen and Factor V assays and, essential to the diagnosis, a low plasminogen level. A major diagnostic difficulty arises from the lability of plasminogen activator, which in vivo has a halflife which appears to be around fifteen minutes; accordingly, if a blood sample is obtained after the phase of activator release has ceased, clot lysis may be normal or even prolonged, especially if previous activator release has resulted in low plasminogen levels. In such circumstances, a firm diagnosis depends on plasminogen assay.
Differentiation ofHyperplasminwmia
from Intravascular Clotting Because of the therapeutic implications it is important, though very difficult when clot lysis is not accelerated, to distinguish between lysis and clotting as causes of acute defibrination. In both conditions, fibrinogen is low, thrombin time and prothrombin time prolonged and Factor V and AHG levels reduced. Plasminogen is probably normal, however, in intravascular clotting and platelets are not affected by a pure hyperplasminmemic state though, of course, theymay be depleted following multiple blood transfusion. Differentiation of clotting from lysis may therefore rest on plasminogen assay with some support from a platelet count. Treatment ofHyperplasmina?mic States with E-aminocaproic Acid (EACA) EACA is a potent inhibitor of a fibrinolytic enzyme system and has an important role in the treatment ofhyperplasminiemic states. A synthetic amino acid with a formula similar to that of lysine (Fig 1) , EACA at a concentration above
Lysine 1 mg/100 ml is an inhibitor of plasminogen activation and, at concentrations above 100 mg/100 ml, is also an inhibitor of plasmin, trypsin and other proteolytic enzymes. Therapeutic levels are probably about 15 mg/100 ml. By an unknown mechanism EACA can also inhibit certain immune responses.
Absorption, Excretion and Dosage ofEACA EACA is rapidly absorbed from the gastrointestinal tract. Peak plasma levels are found about two hours after a single oral dose. Renal excretion is rapid, the greater part of a single dose being recovered unchanged in the urine in twelve hours. As regards dosage, the aim is to achieve a plasma level of 15 mg/100 ml. A loading dose of 4-6 g should be given orally or intravenously followed by 1 g/hour. If the intravenous route is used, the EACA can be given diluted in any intravenous fluid. As hypotension may follow rapid intravenous injection, the loading dose should be spread over thirty minutes.
Side-effects ofEA CA and Contraindications
It is now ciear that EACA carries a risk of inducing vascular occlusion, an effect presumably duto its primary action as a fibrinolytic inhibitor. The risk is particularly real in elderly patients with pre-existing vascular occlusion, to whom EACA should only be given if fibrinolytic activity poses a major threat to life. In animals EACA is teratogenic and it should therefore not be given to women in the early months of pregnancy. In animals it has been reported, in doses higher than those given to man. to cause subendocardial h.emorrhages.
Indicationsfor EACA EACA is indicated when a firm diagnosis of a hyperplasminemic state has been made. Supporting measures include blood transfusion, fibrinogen (8 g intravenously) and hydrocortisone (100 mg hydrocortisone hemisuccinate intravenously; this mitigates certain of the effects of hyperplasminaemia). Where an acute life-threatening haemo-rrhagic state is present and time does not permit full laboratory study, treatment initially should be with blood transfusion and hydrocortisone followed in twenty minutes by fibrinogen, and if in another twenty minutes hemostatic failure persists, EACA should then be given.
Clinical Efficacy ofEA CA Though the circumstances in which hyperplasminoemic states occur and their comparative rarity make an adequate controlled trial difficult or impossible, evidence from well-studied individual cases is now accumulating to suggest that EACA is clinically and biochemically effective in their control.
Other Uses ofEACA in Surgery EACA is also of value after prostatectomy when, by inhibiting physiological levels of urokinase in the urinary tract, it improves post-operative haemostasis: because of concentration in urine, a lower dosage may be given than for systemic fibrinolytic states. A dosage schedule of 6 g per day in divided doses is probably adequate.
Other Fibrinolytic Inhibitors Trasylol, a polypeptide originally isolated from bovine parotid and now commercially prepared from bovine lung, inhibits many proteolytic enzymes including trypsin, plasmin and plasminogen activators. As it also inhibits the early stages of blood thromboplastin formation, it may prove to have an important part to play in the treatment of acute defibrination syndromes in which emergency differentiation of hyperplasminmmia from intravascular clotting poses such a difficult problem. Aminomethyl cyclohexane carboxylic acid, a synthetic amino acid about ten times more potent than EACA in vitro and in vivo as an inhibitor of plasminogen activation, is also in the investigative phase and may come to have an important place in therapy.
Conclusions
Acute fibrinolytic (hyperplasminemia) states, though rare, may occasionally complicate surgical procedures when they induce a life-threatening hemostatic defect. The diagnosis of such states presents a major problem but a specific fibrinolytic inhibitor, EACA, is now available and is effective in their treatment. The lack of rapid simple diagnostic tests for use in acute hmmostatic emergencies is a challenge to those who are involved in research in blood coagulation.
